Archimed to Acquire Esperion Therapeutics for Up To $1.1 Billion
ESPR has more than doubled off its 52-week low of $0.693 on elevated volume (22× avg).
Summary
Esperion Therapeutics has entered into a definitive agreement to be acquired by investment firm Archimed for up to $1.1 billion, taking the company private. This news confirms the acquisition previously reported by Wiseek News and detailed in an SEC DEFA14A filing earlier today, adding the significant total valuation of the deal. The acquisition represents a substantial premium over Esperion's recent market capitalization and is a highly material event for shareholders. Traders will now focus on the closing conditions and timeline for the transaction.
At the time of this announcement, ESPR was trading at $3.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $800.5M. The 52-week trading range was $0.69 to $4.18. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.